FY23 facilities to-a
Active Awarded Last action
- Contract number
- 75N91023F00005
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,111,246
Award facts
- Contract value 52% obligated
- $11,826,515.00 Current and potential, with all options
- Completion date 84% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $70,457 | |
| Funding Only Action | $148,670 | |
| Supplemental Agreement for work within scope | $190,447 | |
| Supplemental Agreement for work within scope | $136,444 | |
| Supplemental Agreement for work within scope | $897,619 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $5,578,825 | |
| Original award | $4,804,053 |
About this award
The National Cancer Institute awarded a $11.83 million delivery order contract to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., on June 28, 2023, for facilities support services. The contract operates under a cost-plus-fixed-fee pricing model with an ultimate completion date of June 24, 2027, and involves no set-aside designation. Work will be performed at the Frederick, Maryland location, where Leidos operates as a Federally Funded Research and Development Center (FFRDC) contractor supporting NCI's biomedical research infrastructure and operations.
Leidos Biomedical Research Inc. specializes in comprehensive biomedical research and facilities management services for federal health agencies, with particular expertise in medical research support, clinical trial administration, laboratory operations, and facility infrastructure. The company's portfolio includes substantial experience managing complex research projects spanning gene therapy development, infectious disease research, vaccine development, and specialized laboratory testing. This delivery order represents part of Leidos' ongoing support to NCI's research mission through its established FFRDC relationship, leveraging the subsidiary's demonstrated technical capabilities in scientific research infrastructure and advanced laboratory operations.
Quick answers
Who was awarded contract 75N91023F00005?
75N91023F00005 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on June 28, 2023.
How much is contract 75N91023F00005 worth?
The government has obligated $6,111,246 on 75N91023F00005. Its current value, with exercised options, is $11,826,515.
Is contract 75N91023F00005 an order under another contract?
Yes. 75N91023F00005 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91023F00005 competed?
The extent of competition for 75N91023F00005 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award